Last reviewed · How we verify
VIMOVO 250/20
VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.
VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers. Used for Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers.
At a glance
| Generic name | VIMOVO 250/20 |
|---|---|
| Also known as | naproxen/esomeprazole |
| Sponsor | Amgen |
| Drug class | NSAID with proton pump inhibitor combination |
| Target | COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Naproxen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Esomeprazole suppresses gastric acid secretion by inhibiting the H+/K+-ATPase pump, protecting the gastric mucosa from NSAID-related damage and ulceration.
Approved indications
- Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers
Common side effects
- Dyspepsia
- Diarrhea
- Gastric ulcer (reduced vs. NSAID alone)
- Headache
- Nausea
Key clinical trials
- A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) (PHASE4)
- Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIMOVO 250/20 CI brief — competitive landscape report
- VIMOVO 250/20 updates RSS · CI watch RSS
- Amgen portfolio CI